WO2025233867 - ANTI-SIGLEC-9 ANTIBODIES AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2025/233867
Publication Date
13.11.2025
International Application No.
PCT/IB2025/054810
International Filing Date
07.05.2025
Title **
[English]
ANTI-SIGLEC-9 ANTIBODIES AND USES THEREOF
[French]
ANTICORPS ANTI-SIGLEC-9 ET LEURS UTILISATIONS
Applicants **
ADAPTAM THERAPEUTICS, S.L.
ASOCIACIÓN CENTRO DE INVESTIGACIÓN COOPERATIVA EN BIOCIENCIAS - CIC BIOGUNE
Inventors
PALAZÓN GARCÍA, Francisco de Asís
BOSCH MARTÍNEZ, Alexandre
Priority Data
24382509.8
10.05.2024
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5516 | |
| EPO | Filing, Examination, Granting | 104666 | |
| Japan | Filing, Examination, Granting | 4864 | |
| South Korea | Filing, Examination, Granting | 7811 | |
| USA | Filing, Examination, Granting | 47590 |
Total:
170,447
Contact Us
Abstract[English]
The present invention provides anti-Siglec-9 antibodies and antigen-binding fragments thereof as well as isolated nucleic acids, vectors, engineered cells, formulations thereof, and methods of use thereof for treating diseases including cancer and bone disease in a human subject. The invention is further directed to bispecific and multispecific antibodies, antibody-drug conjugates and chimeric antigen receptors derived from the anti-Siglec-9 antibodies and fragments thereof.[French]
La présente invention concerne des anticorps anti-Siglec-9 et des fragments de liaison à l'antigène de ceux-ci, ainsi que des acides nucléiques isolés, des vecteurs, des cellules modifiées, des formulations de ceux-ci, et des procédés d'utilisation de ceux-ci pour le traitement de maladies comprenant les cancers et les pathologies osseuses chez un sujet humain. L'invention concerne en outre des anticorps bispécifiques et multispécifiques, des conjugués anticorps-médicament et des récepteurs antigéniques chimériques dérivés des anticorps anti-Siglec-9 et des fragments de ceux-ci.